PDS Biotechnology (PDSB) News Today $1.65 -0.10 (-5.71%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period PDS Biotechnology (PDSB) Receives a Buy from Alliance Global PartnersDecember 20 at 4:05 PM | markets.businessinsider.comPDS Biotechnology (NASDAQ:PDSB) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $21.00 price target on shares of PDS Biotechnology in a research note on Wednesday.December 18 at 8:15 AM | marketbeat.comPDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 6, 2024 | globenewswire.comPDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ETDecember 3, 2024 | globenewswire.comB. Riley Cuts Earnings Estimates for PDS BiotechnologyPDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - B. Riley dropped their FY2024 earnings estimates for shares of PDS Biotechnology in a report released on Monday, November 25th. B. Riley analyst M. Mamtani now expects that the company will post earnings of ($1.12) per share for the year, down fNovember 27, 2024 | marketbeat.comStrategic Changes in PDS Biotechnology’s Clinical Trial Design Position Stock as Attractive Buy OpportunityNovember 26, 2024 | markets.businessinsider.comPDS Biotechnology Shares Down 18% After Phase 3 Trial ModificationsNovember 15, 2024 | marketwatch.comPDS Biotechnology Highlights Clinical Progress and Q3 ResultsNovember 15, 2024 | markets.businessinsider.comPDS Biotechnology: Strategic Advancements and Clinical Progress Drive Buy RatingNovember 15, 2024 | markets.businessinsider.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | msn.comPDS Biotechnology (NASDAQ:PDSB) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $21.00 target price on shares of PDS Biotechnology in a research report on Friday.November 15, 2024 | marketbeat.comPDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comPDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comUncovering Potential: PDS Biotechnology's Earnings PreviewNovember 13, 2024 | benzinga.comStockNews.com Downgrades PDS Biotechnology (NASDAQ:PDSB) to SellStockNews.com cut PDS Biotechnology from a "hold" rating to a "sell" rating in a research report on Saturday.November 9, 2024 | marketbeat.comPDS Biotechnology (NASDAQ:PDSB) Cut to "Sell" at StockNews.comStockNews.com lowered shares of PDS Biotechnology from a "hold" rating to a "sell" rating in a research report on Saturday.November 9, 2024 | marketbeat.comPDS Biotechnology (PDSB) Set to Announce Quarterly Earnings on ThursdayPDS Biotechnology (NASDAQ:PDSB) will be releasing earnings before the market opens on Thursday, November 14, Zacks reports.November 7, 2024 | marketbeat.comPDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern TimeNovember 6, 2024 | globenewswire.comPDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by AnalystsPDS Biotechnology Co. (NASDAQ:PDSB - Get Free Report) has been given an average rating of "Buy" by the five ratings firms that are presently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendaNovember 3, 2024 | marketbeat.comPDS Biotechnology (NASDAQ:PDSB) Stock Rating Upgraded by StockNews.comStockNews.com upgraded PDS Biotechnology from a "sell" rating to a "hold" rating in a research note on Friday.November 1, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for PDS Biotechnology (NASDAQ:PDSB)HC Wainwright restated a "buy" rating and issued a $21.00 target price on shares of PDS Biotechnology in a research note on Thursday.October 24, 2024 | marketbeat.comPDS Biotechnology presents rationale, design for study evaluating PDS01ADCOctober 23, 2024 | markets.businessinsider.comPDS Biotechnology Co. (NASDAQ:PDSB) Receives Consensus Recommendation of "Buy" from AnalystsPDS Biotechnology Co. (NASDAQ:PDSB - Get Free Report) has earned a consensus rating of "Buy" from the five brokerages that are presently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendaOctober 9, 2024 | marketbeat.comBuy Rating Affirmed on PDS Biotechnology Amid Promising PDS0101 Cervical Cancer Trial ResultsOctober 3, 2024 | markets.businessinsider.comPDS Biotechnology's (PDSB) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $21.00 price target on shares of PDS Biotechnology in a report on Wednesday.October 2, 2024 | marketbeat.comPDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and ChemoradiationOctober 2, 2024 | globenewswire.comBuy Rating Justified: PDS Biotechnology’s Versamune HPV Shows Promise in Phase 2 TrialsSeptember 18, 2024 | markets.businessinsider.comPDS Biotechnology (PDSB) Receives a Buy from Noble FinancialSeptember 18, 2024 | markets.businessinsider.comPDS Biotech Announces Updated Data From VERSATILE-002 Phase 2 Study In HNSCCSeptember 16, 2024 | markets.businessinsider.comPDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024September 16, 2024 | markets.businessinsider.comPDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by BrokeragesShares of PDS Biotechnology Co. (NASDAQ:PDSB - Get Free Report) have been assigned an average recommendation of "Buy" from the five brokerages that are currently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a buy recommendation and one has assigned aSeptember 14, 2024 | marketbeat.comPDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024September 9, 2024 | globenewswire.comPDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.comPDS Limited Raises INR 430 Cr in QIP to Fuel Global Expansion and InnovationAugust 29, 2024 | msn.comPDS Biotechnology (NASDAQ:PDSB) Upgraded at Alliance Global PartnersAlliance Global Partners upgraded PDS Biotechnology to a "strong-buy" rating in a report on Wednesday.August 22, 2024 | marketbeat.comPDS Biotechnology Co. (NASDAQ:PDSB) Receives Consensus Rating of "Buy" from BrokeragesPDS Biotechnology Co. (NASDAQ:PDSB - Get Free Report) has been assigned an average recommendation of "Buy" from the five analysts that are currently covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation. The average 12-month price oAugust 20, 2024 | marketbeat.comAlliance Global Partners Increases PDS Biotechnology (NASDAQ:PDSB) Price Target to $7.00Alliance Global Partners lifted their target price on shares of PDS Biotechnology from $5.00 to $7.00 and gave the stock a "buy" rating in a report on Tuesday.August 20, 2024 | marketbeat.comBrokers Offer Predictions for PDS Biotechnology Co.'s FY2024 Earnings (NASDAQ:PDSB)PDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - Research analysts at Cantor Fitzgerald boosted their FY2024 earnings per share estimates for PDS Biotechnology in a research note issued to investors on Wednesday, August 14th. Cantor Fitzgerald analyst L. Chen now expects that the company willAugust 19, 2024 | marketbeat.comPSE bullish on sealing PDS takeover this yearAugust 16, 2024 | msn.comNoble Financial Weighs in on PDS Biotechnology Co.'s Q3 2024 Earnings (NASDAQ:PDSB)PDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - Research analysts at Noble Financial issued their Q3 2024 EPS estimates for PDS Biotechnology in a note issued to investors on Wednesday, August 14th. Noble Financial analyst R. Leboyer forecasts that the company will post earnings per share ofAugust 16, 2024 | marketbeat.comPDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial ResultsAugust 13, 2024 | markets.businessinsider.comPDS rice worth one crore seized in Telangana from Jan to JulyAugust 12, 2024 | msn.comPDS Biotechnology Q2 2024 Earnings PreviewAugust 12, 2024 | msn.comPDS Biotech Announces Abstract Accepted for Oral Presentation at 2024 ASTRO Annual MeetingAugust 8, 2024 | finance.yahoo.comPDS Biotechnology (PDSB) Set to Announce Quarterly Earnings on TuesdayPDS Biotechnology (NASDAQ:PDSB) will be releasing earnings before the market opens on Tuesday, August 13, Zacks reports.August 8, 2024 | marketbeat.comPDS Biotech to Announce Second Quarter Financial Results on August 13, 2024August 7, 2024 | globenewswire.comPDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024August 5, 2024 | finance.yahoo.comPDS Biotech advances to phase 3 trial for HPV cancer therapyAugust 3, 2024 | uk.investing.comOptimistic Buy Rating for PDS Biotechnology Amid Promising Versamune HPV Trial Progress and Strategic FDA AlignmentAugust 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for PDS Biotechnology Amidst Promising Clinical Developments and Regulatory ProgressAugust 2, 2024 | markets.businessinsider.com Get PDS Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now PDSB Media Mentions By Week PDSB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PDSB News Sentiment▼0.150.59▲Average Medical News Sentiment PDSB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PDSB Articles This Week▼32▲PDSB Articles Average Week Get PDS Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PDSB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AMLX News Today LFCR News Today ITOS News Today FHTX News Today ELDN News Today URGN News Today RZLT News Today AVIR News Today CMRX News Today ATYR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PDSB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share PDS Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PDSB Stock Alerts